BridgeMD
Tests treatment safety and results for Advanced Malignant Solid Tumor
Official title A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
ClinicalTrials.gov ID: NCT05477849
What this study is testing
What is Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection?
Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for advanced malignant solid tumor.
Also referred to as VG2025.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Signed written informed consent form.
- Age 18 to 75 years (inclusive), male or female.
- Subject with advanced malignant solid tumors who have failed standard treatment and for whom there is no effective treatment at this stage.
- Eligible patients of childbearing potential (male and female) must agree to use a reliable method of contraception during the trial and for at least...
You likely can't join if
- people who have received other unlisted drugs clinical trial treatment 4 weeks before the first dose of the study drug.
- people who underwent major organ surgery (excluding needle biopsy) or had significant trauma 4 weeks before the first dose of the study drug.
- In the herpes simplex virus recurrence and infection period, and there are corresponding clinical manifestations, such as oral herpes labialis...
- Other active uncontrolled infection.
- Known alcohol or drug dependence.
- people with mental disorders or poor compliance.
See the full eligibility criteria
- Signed written informed consent form.
- Age 18 to 75 years (inclusive), male or female.
- Subject with advanced malignant solid tumors who have failed standard treatment and for whom there is no effective treatment at this stage.
- Eligible patients of childbearing potential (male and female) must agree to use a reliable method of contraception during the trial and for at least 90 days after dosing; females of childbearing potential must have a...
- people who have received other unlisted drugs clinical trial treatment 4 weeks before the first dose of the study drug.
- people who underwent major organ surgery (excluding needle biopsy) or had significant trauma 4 weeks before the first dose of the study drug.
- In the herpes simplex virus recurrence and infection period, and there are corresponding clinical manifestations, such as oral herpes labialis, herpetic keratitis, herpetic dermatitis, genital herpes and so on.
- Other active uncontrolled infection.
- Known alcohol or drug dependence.
- people with mental disorders or poor compliance.
- Women who are pregnant or breastfeeding.
- people in the opinion of the investigator are not suitable for this clinical study due to other serious systemic diseases or other reasons.
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.